Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104713 | 0.84 | NPC1 (0.48) | NPC1L3MBTL1CYP3A4LMNATRPM8 | |
| SCHEMBL104712 | 0.84 | NPC1 (0.48) | NPC1L3MBTL1CYP3A4LMNATRPM8 | |
| SCHEMBL16098956 | 0.77 | ZDHHC20 (0.39) | NPC1L3MBTL1LMNAPSMB5MMP1 | |
| SCHEMBL9113596 | 0.77 | CA12 (0.41) | NPC1L3MBTL1CYP3A4LMNAPSMB5 | |
| SCHEMBL17666080 | 0.75 | NPC1 (0.42) | NPC1L3MBTL1CYP3A4LMNATRPM8 | |
| SCHEMBL17666075 | 0.75 | NPC1 (0.42) | NPC1L3MBTL1CYP3A4LMNATRPM8 | |
| SCHEMBL871607 | 0.73 | — | — | |
| SCHEMBL10706477 | 0.72 | CYP3A4 (0.36) | NPC1L3MBTL1CYP3A4LMNATRPM8 | |
| SCHEMBL10706470 | 0.72 | CYP3A4 (0.36) | NPC1L3MBTL1CYP3A4LMNATRPM8 | |
| SCHEMBL1630772 | 0.71 | NPC1 (0.54) | NPC1L3MBTL1CYP3A4LMNATRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | NPC1 2947/4885L3MBTL1 3599/4885CYP3A4 400/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | NPC1 3482/4885L3MBTL1 3097/4885CYP3A4 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.